H9提取物对Trastuzumab的药理动力学及其组合没有干扰
Seung Yon Han1, Jeong-Eun Yu1, Byoung Hoon You1
1College of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University_Seoul, 32 Dongguk-ro, Ilsandong-gu, Goyang-si 10326, Gyeonggi-do, Republic of Korea.
H9提取物 (H9) 在小鼠中不会改变trastuzumab的暴露,即使在用于协同治疗乳腺癌时. 这一发现对于理解组合治疗的安全性和有效性至关重要.
科学领域:
- 药理学和瘤学 药理学和瘤学
- 药物代谢和药理动力学
背景情况:
- 特拉斯图祖马布是治疗HER2阳性乳腺癌的关键疗法,但耐药性和毒性需要组合策略.
- 在乳腺癌中,Trastuzumab和H9提取物 (H9) 的协同作用需要对它们的联合药理动力学特征进行研究.
- 了解药物暴露对于评估组合疗法的有效性和安全性至关重要.
研究的目的:
- 为了描述Trastuzumab在小鼠中的药理动力学.
- 为了确定H9提取物对Trastuzumab药理动学的影响,当联合使用时.
- 为了评估H9是否影响Trastuzumab在协同组合剂量的暴露.
主要方法:
- 在小鼠静脉注射 (1-10毫克/公斤) 后分析了特拉斯图祖马布的药理动力.
- 小鼠接受单次,2周或3周的口服H9 (500毫克/公斤) 治疗,并与Trastuzumab结合使用.
- 测量了trastuzumab的血度和组织分布,以评估药理动力学变化.
主要成果:
- 在测试剂量范围内,trastuzumab表现出线性药理动力学.
- 单次或为期2周的H9治疗都没有改变Trastuzumab的药理动力学特征.
- 多重组合治疗 (3周Trastuzumab与2周H9) 与单独Trastuzumab相比没有改变Trastuzumab的药理动力学.
- H9没有影响Trastuzumab有限的组织分布,组织与血的比率始终低于1.0.
结论:
- H9提取物不会显著改变小鼠对Trastuzumab的全身或局部暴露.
- 特拉斯图祖马布的药用动力学概况保持一致,不论是单次或多次与H9联合使用.
- 这些发现支持结合Trastuzumab和H9的安全性,因为表明没有不良的药理学相互作用.
更多相关视频
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
相关概念视频
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Hepatic Drug Clearance: Role of Transporters
